References
- Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control. CDC. Prescription painkiller overdoses. November 2011. Available at: http://www.cdc.gov/HomeandRecreationalSafety/pdf/PolicyImpact-PrescriptionPainkillerOD.pdf [Last accessed November 2013]
- Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013. Available at: http://www.samhsa.gov/data/NSDUH/2012SummNatFindDetTables/NationalFindings/NSDUHresults2012.pdf [Last accessed September 2013]
- Office of National Drug Control Policy. Epidemic: Responding to America’s prescription drug abuse crisis. 2011. Available at: http://www.whitehouse.gov/sites/default/files/ondcp/policy-and-research/rx_abuse_plan.pdf [Last accessed March 2014]
- U.S. Food and Drug Administration. FDA introduces new safety measures for extended-release and long-acting opioid medications. 2012. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310870.htm [Last accessed January 2013]
- Vital signs: overdoses of prescription opioid pain relievers – United States, 1999–2008. Morb Mortal Wkly Rep 2011;60:1487-92
- Stewart WF, Ricci JA, Chee E, et al. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003;290:2443-54
- U.S. Food and Drug Administration. Guidance for Industry. Abuse-Deterrent Opioids – Evaluation and Labeling. Draft Guidance. 2013. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf [Last accessed February 2013]
- Woodcock J. A difficult balance – pain management, drug safety, and the FDA. N Engl J Med 2009;361:2105-7
- FDA approves abuse-deterrent labeling for reformulated OxyContin. Silver Spring, MD: U.S. Food and Drug Administration, 2013. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm348252.htm [Last accessed 16 August 2013]
- Alexander L, Mannion RO, Weingarten B, et al. Development and impact of prescription opioid abuse deterrent formulation technologies. Drug Alcohol Depend 2014: published online 16 February 2014, doi:10.1016/j.drugalcdep.2014.02.006
- FDA Statement: Original Opana ER Relisting Determination. Silver Spring, MD: U.S. Food and Drug Administration, 2013. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm351357.htm [Last accessed 4 February 2014]
- Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain 2013;14:351-8
- Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med 2012;367:187-9
- White AG, Birnbaum HG, Mareva MN, et al. Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm 2005;11:469-79
- White AG, Birnbaum HG, Rothman DB, et al. Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction. Appl Health Econ Health Policy 2009;7:61-70